Abstract:This article presented the metabolic reprogramming of tumor cells to adapt to their microenvironment distinct from normal cells. And this study reviewed the driving factors of metabolic reprogramming, the specific metabolic pathway changes affected, and the related treatment options, in order to provide some suggestions for future tumor treatment. Cancer cells characterized by uncontrolled growth and proliferation require altered metabolic processes to maintain this characteristic. Metabolic reprogramming is a process mediated by various factors, including oncogenes, tumor suppressor genes, changes in growth factors, and tumor–host cell interactions, which help to meet the needs of cancer cell anabolism and promote tumor development. Metabolic reprogramming in tumor cells is dynamically variable, depending on the tumor type and microenvironment, and reprogramming involves multiple metabolic pathways. These metabolic pathways have complex mechanisms and involve the coordination of various signaling molecules, proteins, and enzymes, which increases the resistance of tumor cells to traditional antitumor therapies. With the development of cancer therapies, metabolic reprogramming has been recognized as a new therapeutic target for metabolic changes in tumor cells. Therefore, understanding how multiple metabolic pathways in cancer cells change can provide a reference for the development of new therapies for tumor treatment. Here, we systemically reviewed the metabolic changes and their alteration factors, together with the current tumor regulation treatments and other possible treatments that are still under investigation. Continuous efforts are needed to further explore the mechanism of cancer metabolism reprogramming and corresponding metabolic treatments.

MAT2A inhibition combats metabolic and transcriptional reprogramming in cancer

Acetylation of MAT IIα represses tumour cell growth and is decreased in human hepatocellular cancer

Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancer

MAT2B Mediates Invasion and Metastasis by Regulating EGFR Signaling Pathway in Hepatocellular Carcinoma

MAT2a and AHCY Inhibition Disrupts Antioxidant Metabolism and Reduces Glioblastoma Cell Survival

Activation of MAT2A-ACSL3 pathway protects cells from ferroptosis in gastric cancer

Discovery of Novel MAT2A Inhibitors by an Allosteric Site-Compatible Fragment Growing Approach

Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression

Deregulated 14-3-3ζ and methionine adenosyltransferase α1 interplay promotes liver cancer tumorigenesis in mice and humans

Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability

Metabolic reprogramming in colorectal cancer: regulatory networks and therapy

Targeting methionine metabolism in cancer: opportunities and challenges

Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice

Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches

Metabolism of Amino Acids in Cancer

Metabolic reprogramming in cancer: Mechanisms and therapeutics

Metabolic reprograming of tumor-associated macrophages

Altered metabolism in cancer: insights into energy pathways and therapeutic targets

SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S-adenosylmethionine-competitive or the methylthioadenosine-cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase-deleted tumors

Acetylation Control of Metabolic Enzymes in Cancer: an Updated Version

Metabolic reprogramming of carcinoma-associated fibroblasts and its impact on metabolic heterogeneity of tumors